



Dermapharm Holding SE: Annual General Meeting approves dividend payout of EUR 0.80 per share

- » Annual General Meeting successfully held virtually
- » Management Board and Supervisory Board discharged by a large majority
- » Important milestones achieved in fiscal year 2019
- » Continuation of the profitable growth course in 2020
- » New Management Board members introduce themselves

Grünwald, June 17, 2020 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, successfully held its 2020 Annual General Meeting today. 90.61% of the share capital represented was present at the virtual event. All items on the agenda were approved by a large majority.

At the Annual General Meeting, the Management Board reported in detail on the operational and strategic development of Dermapharm Holding SE in fiscal year 2019 as well as in the first quarter of 2020, once again achieving significant milestones in the implementation of the company’s strategy, as well as significant growth in sales and earnings. At the same time, the Management Board provided an outlook for the current fiscal year 2020.

“We successfully continued on our growth course in 2019 as well by introducing new products, continuing with our internationalization and through the acquisitions we made and set the course for sustainable and profitable growth in the years ahead. We also took an important step with the new logistics center in Brehna near Leipzig. Our dividend policy allows our shareholders to participate directly in our company’s success,” said Dr Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.

The Management Board and Supervisory Board were discharged for fiscal year 2019 by a large majority at the Annual General Meeting. The Annual General Meeting followed the proposal of the Management Board and resolved to distribute a dividend of EUR 0.80 per no-par value share entitled to a dividend.

For 2020, Dermapharm considers itself well prepared in view of the experience and results to date with the current corona pandemic and does not expect any reportable restrictions in production with direct consequences on market supply. As Dermapharm’s main production sites have been classified as companies with critical infrastructure for the public community, production operations can be maintained without any interruptions.

Dr Jürgen Ott and Hilde Neumeyer introduced themselves to the shareholders as new members of the Management Board at the virtual Annual General Meeting. Dr Ott is Dermapharm’s Chief Marketing Officer and has been responsible in this function since October 1, 2019. With his unique experience in the field of OTC and phytopharmaceuticals, Dr Ott provides additional new impulses for the positioning of our branded pharmaceuticals. Hilde Neumeyer will take over as Chief Financial Officer from Stefan Hümer on July 1, 2020, who will leave the company for personal reasons at his own request when his contract expires. The Supervisory Board thanks Mr Hümer for his great services to the company and wishes him all the best for the future.

The detailed voting results on the respective agenda items will be published promptly on the website ir.dermapharm.de under the heading “Annual General Meeting.”



Company profile:

Dermapharm – Pharmaceutical Excellence "Made in Germany"

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company's integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a trained medical and pharmaceutical sales force. Dermapharm has more than 250 active pharmaceutical ingredients for more than 900 marketing authorizations (Arzneimittelzulassungen), which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This range makes the company unique. Besides Germany, the company's core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm's business model also includes a parallel import business that operates under the "axicorp" brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2019. In the "Herbal extracts" segment, Dermapharm has access to the growth market for herbal pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of herbal extracts and natural active ingredients.

With a consistent R&D strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.

Contacts

Investor Relations & Corporate Communications
Britta Hamberger
Phone: +49 (0)89 – 64186-233
Fax: +49 (0)89 – 64186-165
E-mail: ir@dermapharm.com

cometis AG
Claudius Krause
Phone: +49 (0)611 – 205855-28
Fax: +49 (0)611 – 205855-66
E-mail: ir@dermapharm.com